PD-L1 CD47 Bispecific single domain antibodies against PD-L1 and CD47 and use thereof

• Main Authors: LEE SANG BEUM, SEONG SEUNG YONG
• Format: Patent
• Language: English; Korean
• Published: 26.08.2022
• Subjects: CHEMISTRY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; TESTING

The present invention relates to a bispecific single domain antibody against PD-L1 and CD47 and a use thereof. Specifically, the present invention manufactures a single domain antibody bispecifically binding to PD-L1 and CD47, immune checkpoint proteins, and confirms the affinity and antitumor effect with respect to immune antigens thereof, thereby usefully using the bispecific single domain antibody for immunotherapy as an immune checkpoint inhibitor. 본 발명은 PD-L1 및 CD47에 대한 이중특이적 단일 도메인 항체 및 이의 용도에 관한 것으로, 구체적으로 면역관문 단백질(immune checkpoint protein)인 PD-L1 및 CD47에 이중특이적으로 결합하는 단일 도메인 항체를 제작하였고, 이의 면역 항원에 대한 친화성 및 항종양 효과를 확인하였으므로, 상기 이중특이적 단일 도메인 항체를 면역관문 억제제로 면역항암요법에 유용하게 이용할 수 있다.